Boehringer Ingelheim
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS48
PHASE 3 / 2-328
RECRUITING29
READOUTS ≤12 MONTHS16
READOUT SLIPPED >6 MO28%
Delay Index: of 25 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Boehringer Ingelheim on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| zongertinib NCT06151574 |
P3 | Active, not recruiting | Lung Cancer, Non-squamous, Non-small Cell | 428 | 2026-12-10 (-4 mo) |
| BI 1584862 NCT06769048 |
P2 | Active, not recruiting | Geographic Atrophy | 150 | 2026-12-22 |
| BI 690517 NCT06531824 |
P3 | Active, not recruiting | Kidney Disease, Chronic | 8371 | 2026-12-31 (-20 mo) |
| BI 764524 NCT06321302 |
P2 | Recruiting | Diabetic Retinopathy | 175 | 2027-03-05 (+8 mo) |
| BI 765423 NCT07036523 |
P2 | Active, not recruiting | Idiopathic Pulmonary Fibrosis | 81 | 2027-03-11 |
| Low dose BI 3812465 NCT07553429 |
P1/2 | Recruiting | Diabetic Macular Edema | 49 | 2027-03-23 |
| BI 1291583 NCT05846230 |
P2 | Active, not recruiting | Bronchiectasis | 268 | 2027-03-31 (+13 mo) |
| Nerandomilast NCT06806592 |
P3 | Active, not recruiting | Interstitial Lung Diseases; Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases | 414 | 2027-04-15 |
| Empagliflozin NCT07107945 |
P3 | Active, not recruiting | Chronic Kidney Disease | 135 | 2027-04-16 (-14 mo) |
| FIBRONEER™-ON NCT06238622 |
P3 | Active, not recruiting | Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis | 1666 | 2027-04-28 |
| BI 1291583 NCT06872892 |
P3 | Recruiting | Bronchiectasis | 1755 | 2027-06-15 (-15 mo) |
| BI 3034701 NCT07662122 |
P2 | Active, not recruiting | Obesity; Overweight | 345 | 2027-06-26 |
| BI 3032950 intravenous (Part A) NCT06636656 |
P2 | Recruiting | Ulcerative Colitis | 80 | 2027-07-30 (+15 mo) |
| BI 3802876 NCT07325526 |
P2 | Recruiting | Liver Cirrhosis | 30 | 2027-08-05 |
| Zongertinib NCT07486817 |
P2 | Recruiting | Lung Cancer, Non-squamous, Non-small Cell | 60 | 2027-08-12 |
| TENACITY NCT07361302 |
P3 | Recruiting | Acute Ischemic Stroke | 1325 | 2027-10-02 |
| BI 764532, dose 1 NCT05882058 |
P2 | Recruiting | Small Cell Lung Carcinoma; Neuroendocrine Neoplasms | 204 | 2027-12-17 (+39 mo) |
| Survodutide NCT07754461 |
P3 | Recruiting | Type 2 Diabetes | 600 | 2028-01-17 |
| BI 764198 NCT07355296 |
P2 | Recruiting | Proteinuric Kidney Diseases | 132 | 2028-01-20 |
| BI 3810477 NCT07926321 |
P2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | 2028-01-27 |
| BI 1815368 NCT06962839 |
P2 | Recruiting | Macular Edema | 300 | 2028-03-01 (+6 mo) |
| vicadrostat NCT06424288 |
P3 | Recruiting | Heart Failure | 6712 | 2028-05-22 (+6 mo) |
| Obrixtamig NCT07929051 |
P3 | Not yet recruiting | Advanced Cancer | 68 | 2028-07-03 |
| Survodutide NCT07850050 |
P3 | Not yet recruiting | Obesity | 600 | 2028-07-26 |
| obrixtamig NCT07472517 |
P3 | Recruiting | Small Cell Lung Cancer (SCLC); Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | 2028-09-09 |
| Zongertinib NCT06581432 |
P2 | Recruiting | Solid Tumours | 588 | 2028-11-30 (+15 mo) |
| Nerandomilast NCT07540988 |
P3 | Recruiting | Interstitial Lung Diseases | 466 | 2028-12-05 |
| BI 764198 NCT07220083 |
P3 | Recruiting | Focal Segmental Glomerulosclerosis | 286 | 2028-12-27 (-14 mo) |
| Zongertinib NCT06324357 |
P1/2 | Recruiting | Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma | 910 | 2029-01-08 (+23 mo) |
| vicadrostat NCT06935370 |
P3 | Recruiting | Heart Failure | 4200 | 2029-02-04 |
| BI 3000202 NCT07409181 |
P2 | Recruiting | Systemic Lupus Erythematosus | 405 | 2029-02-04 |
| Nerandomilast NCT07366034 |
P3 | Recruiting | Fibrosing Interstitial Lung Disease | 35 | 2029-04-27 |
| Survodutide NCT07850063 |
P3 | Not yet recruiting | Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease | 600 | 2029-04-29 |
| Nerandomilast NCT07201922 |
P3 | Recruiting | Familial Pulmonary Fibrosis; Interstitial Lung Abnormalities | 80 | 2029-05-14 |
| Survodutide NCT06632457 |
P3 | Recruiting | Metabolic Dysfunction Associated Steatohepatitis | 1590 | 2029-06-05 |
| verducatib NCT07915219 |
P3 | Not yet recruiting | Bronchiectasis | 1500 | 2029-07-31 |
| Survodutide NCT07855900 |
P3 | Not yet recruiting | Obesity | 350 | 2029-11-06 |
| Verducatib NCT07907991 |
P3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1800 | 2029-11-12 |
| Obrixtamig NCT07544654 |
P3 | Recruiting | Extrapulmonary Neuroendocrine Cancer (epNEC) | 390 | 2029-12-13 |
| Vicadrostat NCT07064473 |
P3 | Recruiting | Diabetes Mellitus, Type 2; Hypertension | 11800 | 2029-12-14 |
| VERANDA™-SSc NCT07497087 |
P3 | Recruiting | Systemic Sclerosis | 448 | 2030-02-26 |
| VERANDA™-IIM NCT07789015 |
P3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | 2030-03-21 |
| Obrixtamig NCT07843940 |
P1/2 | Recruiting | Extensive-stage Small Cell Lung Carcinoma; Advanced Small Cell Lung Cancer | 55 | 2030-04-17 |
| Obrixtamig NCT07707895 |
P1/2 | Recruiting | Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma | 60 | 2030-04-26 |
| Brigimadlin NCT06619509 |
P2 | Active, not recruiting | Solid Tumours | 90 | 2030-12-30 (-72 mo) |
| Survodutide NCT06632444 |
P3 | Recruiting | Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis | 1800 | 2031-12-27 |
| Zongertinib NCT07195695 |
P3 | Recruiting | Non-small Cell Lung Cancer | 400 | 2032-02-26 |
| BI 3720931 NCT06962852 |
P1/2 | Active, not recruiting | Cystic Fibrosis | 5 | 2040-10-29 (-83 mo) |